然而，在拉米夫定的治疗过程中，并没有有效的血清标志物能预测变异的早期发生。
However, there is no useful serum marker that can predict early emergence of mutants during LAM therapy.
目的探讨维持性血液透析（MHD）患者血液标志物对心血管疾病预测的临床意义。
Objective To explore the clinical significance of blood markers of MHD(maitenance hemedialyses) patients to the prediction of cardiovascular disease(CVD).
并且双标志物联合检测较单标志物检测对预测复发具有更高的敏感性。
Furthermore, the two-marker detection had a higher specificity for prediction of metastatic recurrence than single marker detection.
应用推荐